The effectiveness and cost effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part review of technology appraisal 118)

a systematic review and economic model

Martin Hoyle, Louise Crathorne, Jaime Peters, Tracey Jones-Hughes , Chris Cooper, Mark Napier, Paul Tappenden, Chris Hyde

Research output: Book/ReportCommissioned report

Original languageEnglish
PublisherUniversity of Exeter
Commissioning bodyNational Institute for Health and Care Excellence (NICE)
Number of pages214
Publication statusPublished - 2011
Externally publishedYes

Cite this